For more than a century, the global fight against diabetes and metabolic disease has been anchored to treatment models that place daily burden, invasive delivery, and long-term complexity at the center of patient care. As prevalence accelerates and healthcare systems strain under the weight of chronic disease management, the industry is being compelled to rethink not just therapies, but the very assumptions that govern how biologic medicines are delivered and experienced.
Within this evolving landscape, a new class of innovators is emerging—leaders who view scientific advancement not as an endpoint, but as a platform for redesigning access, adherence, and real-world impact. Among the most consequential of these shifts is the pursuit of oral biologic therapies capable of preserving clinical integrity while aligning how patients actually live.
At the forefront of this transformation stands Glen Travers, Co-Founder and Director of Diabetology Limited, whose career has been defined by an uncommon ability to translate complex science into scalable healthcare solutions.
A Career Defined by Vision, Discipline, and Impact
Glen Travers’ journey began in Perth, Western Australia, where he trained as a chartered accountant and co-founded Western Capital Ltd, an equity bank that scaled rapidly to a market capitalisation of $700 million within three years. While this early success established his reputation as a disciplined financial strategist, it was his exposure to breakthrough medical innovation that ultimately reshaped his leadership trajectory. Working closely with inventions behind two of Australia’s most significant medical advances, including a future Nobel laureate, Glen Travers witnessed the profound impact that science could have when guided by entrepreneurial execution.
This experience marked a decisive shift in his purpose. He relocated to London to co-found Cortecs International Ltd, a biopharmaceutical company that reached a $1 billion valuation and pioneered point-of-care diagnostics along with oral delivery technologies for vaccines, proteins, peptides, and macromolecules.
Building on this foundation, Glen Travers went on to establish the Proxima Concepts Group in 2000 and Diabetology Ltd in 2003, committing his leadership to addressing systemic healthcare challenges. By 2009, his focus turned toward redefining treatment pathways for diabetes and obesity, directing his expertise toward the development of oral GLP-1 receptor agonists. Across each phase of his career, Travers’ leadership has been defined by a consistent objective: translating complex science into scalable solutions capable of improving lives on a global scale.
A Century-Old Assumption in Diabetes Care
Glen Travers’ decision to focus on diabetes and metabolic disease emerged from a clear-eyed assessment of global healthcare realities rather than academic curiosity alone. He recognised that metabolic disorders represent one of the most widespread and economically destabilising health challenges of the modern era, affecting populations at a scale that demands systemic solutions. What concerned him most was not only the prevalence of these conditions but also the limitations of existing treatment models that place long-term burdens on patients and healthcare systems alike. Travers viewed this gap as both a leadership responsibility and an opportunity to drive meaningful change.
Guided by a belief that effective therapies must align with human behaviour and long-term adherence, he became determined to challenge entrenched assumptions around how complex biologic treatments are delivered. His focus narrowed on advancing oral therapeutic solutions that could integrate more naturally into patients’ lives while maintaining physiological integrity. This strategic choice reflects Travers’ broader leadership philosophy: addressing the most difficult problems by rethinking foundational approaches, and committing to solutions that balance scientific rigor with real-world impact.
Challenging Orthodoxy at Scale
Innovation in healthcare rarely follows a straight path, and Travers’ work in oral insulin development was no exception. From the beginning, he faced widespread skepticism that such therapies could be delivered effectively through the gastrointestinal tract. Rather than retreating from this resistance, he chose persistence grounded in evidence and disciplined execution.
Under his leadership, the Capsulin formulation progressed through rigorous clinical validation, culminating in a Phase 2b study that demonstrated meaningful reductions in key metabolic markers without episodes of hypoglycaemia across extensive dosing. For Glen Travers, this outcome was not merely a scientific milestone but a leadership imperative. He viewed safety and tolerability as essential conditions for moving insulin earlier in the treatment pathway, believing that earlier intervention could fundamentally alter the long-term trajectory of diabetes care.
The Responsibility of Vision
For Glen Travers, leadership is defined by vision, resilience, and service, applied with discipline and intent. He believes effective leadership begins with the ability to recognise opportunities before they are widely understood, and to translate that foresight into practical pathways that enable progress. This requires not only strategic clarity, but also the patience and resolve to guide complex ideas toward real-world outcomes.
Equally central to his approach is the role of listening and empowerment. Travers views leadership as a responsibility to cultivate capable teams, remain grounded in purpose, and sustain alignment during periods of uncertainty. He does not measure success by valuation or scale alone. Instead, he assesses leadership through its consequences, namely the problems addressed, the lives impacted, and the enduring value created beyond the organisation itself.
Education as a Leadership Multiplier
Education has been central to how I think about leadership and progress. I have been actively involved with the Young Presidents’ Organization at both the European and International Board levels, where education plays a critical role in developing responsible, globally minded CEO leaders. Alongside this, I have chaired educational charities focused on empowering young women, an area I believe is essential for building stronger leadership ecosystems in the future. I am also proud to serve on the University of Western Australia Business School Ambassadorial Council in the UK. For me, education is not just about knowledge acquisition; it is about creating the conditions where innovation, responsibility, and compassion can work together to drive meaningful change.
The Future of Oral Therapeutics
Glen Travers’ immediate focus is on advancing Diabetology Ltd into its next phase of clinical and organisational maturity. He is currently preparing the company for Phase 3 clinical trials of its oral insulin program, a step that reflects both scientific confidence and long-term strategic intent. In parallel, he is expanding development efforts across oral GLP-1 receptor agonists and dual agonist therapies aimed at addressing obesity, an area he views as an increasingly urgent global health priority.
Under his leadership, preclinical research has demonstrated that oral delivery through the Axcess platform can achieve meaningful biopotencies for established GLP-1 molecules such as semaglutide and exenatide, while simultaneously reducing systemic exposure and associated side effects. These findings have reinforced Travers’ conviction that his Axcess system oral delivery may offer not only greater patient acceptance, but also improved tolerability for chronic, lifelong treatment. Observations of depot effects within intestinal tissues further suggest the potential for prolonged therapeutic action, a characteristic he considers critical for elegant and sustainable disease management. Collectively, these developments guide his current leadership priorities, which centre on translating validated science into therapies capable of enduring regulatory, clinical, and real-world demands.
An open letter to emerging leaders in science and innovation
Dear Future Leader,
I write this with one clear purpose: to remind you why you started.
The science will challenge you. The funding cycles will test you. But if your mission is clear—if you’re solving a problem that truly matters—you’ll find the resilience to keep going. Surround yourself with people who share your values, and never lose sight of the lives behind the data.
Sincerely,
A Fellow Leader
Glen Travers, Co-Founder/Director, Diabetology Limited
| Quick Takes | |
| One tool or app | Microsoft Co-Pilot |
| One quote | ‘Perception becomes reality’ |
| One piece of advice | Stay authentic to your Intentions and don’t forget the importance of those immediately around you including your loved ones and your community |
| One movie or book | Movie: The Discovery of Helicobacter Pylori Book: “Who Moved My Cheese” by Spencer Johnson |
